AIM - AIM ImmunoTech Inc.
AIM ImmunoTech Inc is an immuno-pharma company focused on research and development of therapeutics to treat immune disorders, viral and cancer diseases. AIM's flagship products include Ampligen (Rintatolimod), a drug of large macromolecular RNA molecules for cancer and viral diseases and drug Alferon N Injection for a category of STD infection. Clinical trials of Ampligen include studies of cancer patients with renal cell carcinoma, malignant melanoma, colorectal cancer, advanced recurrent ovarian cancer and triple negative metastatic breast cancer. The company is also advancing Ampligen as a potential treatment for COVID-19. FDA has authorized the first human trial assessing the safety and effectiveness of Ampligen in combination with interferon alfa-2b, in cancer patients with COVID-19.
Recently reported position changes by institutional investors
Recent trades by U.S. Senators
No data for this ticker
Recent trades by U.S. Representatives
No data for this ticker
Quarterly net insider trading by a company's directors and management
Flights by private jets registered to AIM
No data for this ticker
Federal grants, loans, and purchases. Click on a date for more info.
No data for this ticker
